Attached files
| file | filename |
|---|---|
| 10-K - NEKTAR THERAPEUTICS | v176023_10k.htm |
| EX-3.6 - NEKTAR THERAPEUTICS | v176023_ex3-6.htm |
| EX-32.1 - NEKTAR THERAPEUTICS | v176023_ex32-1.htm |
| EX-21.1 - NEKTAR THERAPEUTICS | v176023_ex21-1.htm |
| EX-31.1 - NEKTAR THERAPEUTICS | v176023_ex31-1.htm |
| EX-31.2 - NEKTAR THERAPEUTICS | v176023_ex31-2.htm |
| EX-10.16 - NEKTAR THERAPEUTICS | v176023_ex10-16.htm |
Exhibit
23.1
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We
consent to the incorporation by reference in the Registration Statements (Form
S-8 Nos. 333-07969, 333-59735, 333-65919, 333-74669, 333-32788, 333-54078,
333-55032, 333-67342, 333-71936, 333-76638, 333-98321, 333-103040, 333-117975,
333-136498, 333-145259 and 333-153106) pertaining to the amended and restated
1994 Equity Incentive Plan, the 1998 Non-Officer Equity Incentive Plan, the 2000
Non-Officer Equity Incentive Plan, the 401(k) Retirement Plan, the Employee
Stock Purchase Plan, the 2000 Equity Incentive Plan, the 2008 Equity Incentive
Plan, the Bradford Particle Design plc Share Option Schemes, and the Shearwater
Corporation 1996 Nonqualified Stock Option Plan, and in the Registration
Statements (Form S-3 Nos. 333-54080, 333-108859, 333-120009, 333-67340,
333-130591) of Nektar Therapeutics and in the related Prospectuses of our
reports dated March 2, 2010, with respect to the consolidated financial
statements and schedule of Nektar Therapeutics, and the effectiveness of
internal control over financial reporting of Nektar Therapeutics, included in
this Annual Report (Form 10-K) for the year ended December 31,
2009.
/s/ Ernst
& Young
LLP
Palo
Alto, California
March 2,
2010